← Leaderboards
Matthew J Ewend
University Of North Carolina Chapel Hill
$6,239,820
Attributed
$6,239,820
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$6,239,820 · 4
By mechanism
M01$6,239,820 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Stephen Bernard$2,912,053
- Thomas Shea$5,623,497
- Brent W Weston$1,813,433
- Stephen J Bernard$0
- David W Ollila$95,068
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationGliomaClinical ResearchHuman SubjectCombination Cancer TherapyCarmustineNeoplasm /Cancer Radiation TherapyNeoplasm /Cancer ChemotherapyAdult Human (21+)Clinical TrialsNeoplasm /Cancer ImmunotherapyComputed Axial TomographyImmunomodulatorsIntraarterial AdministrationLevamisoleCis Platinum CompoundTissue /Cell CultureChild (0-11)Neoplasm /Cancer SurgeryNeuropsychological TestsProcarbazineDrug Screening /Evaluation
Grant awards (28)
BCNU, PROCARBAZINE AND RADIOTHERAPY IN TREATMENT OF ANAPLASTIC GLIOMAS$190,747
M01 · FY2002 · RR
TREATMENT OF ANAPLASTIC GLIOMAS WITH CONCOMITANT CISPLATIN AND RADIOTHERAPY$190,747
M01 · FY2002 · RR
IMMUNOTHERAPY FOR MALIGNANT GLIOMAS$190,747
M01 · FY2002 · RR
ACTIVE IMMUNOTHERAPY FOR PATIENTS WITH ANAPLASTIC GLIOMA$190,747
M01 · FY2002 · RR
BCNU, PROCARBAZINE AND RADIOTHERAPY IN TREATMENT OF ANAPLASTIC GLIOMAS$294,555
M01 · FY2001 · RR
ACTIVE IMMUNOTHERAPY FOR PATIENTS WITH ANAPLASTIC GLIOMA$294,555
M01 · FY2001 · RR
TREATMENT OF ANAPLASTIC GLIOMAS WITH CONCOMITANT CISPLATIN AND RADIOTHERAPY$294,555
M01 · FY2001 · RR
IMMUNOTHERAPY FOR MALIGNANT GLIOMAS$294,555
M01 · FY2001 · RR
IMMUNOTHERAPY FOR MALIGNANT GLIOMAS$190,747
M01 · FY2001 · RR
ACTIVE IMMUNOTHERAPY FOR PATIENTS WITH ANAPLASTIC GLIOMA$190,747
M01 · FY2001 · RR
TREATMENT OF ANAPLASTIC GLIOMAS WITH CONCOMITANT CISPLATIN AND RADIOTHERAPY$190,747
M01 · FY2001 · RR
BCNU, PROCARBAZINE AND RADIOTHERAPY IN TREATMENT OF ANAPLASTIC GLIOMAS$190,747
M01 · FY2001 · RR
BCNU, PROCARBAZINE AND RADIOTHERAPY IN TREATMENT OF ANAPLASTIC GLIOMAS$294,555
M01 · FY2000 · RR
ACTIVE IMMUNOTHERAPY FOR PATIENTS WITH ANAPLASTIC GLIOMA$294,555
M01 · FY2000 · RR
ACTIVE IMMUNOTHERAPY FOR PATIENTS WITH ANAPLASTIC GLIOMA$294,555
M01 · FY2000 · RR
TREATMENT OF ANAPLASTIC GLIOMAS WITH CONCOMITANT CISPLATIN AND RADIOTHERAPY$294,555
M01 · FY2000 · RR
TREATMENT OF ANAPLASTIC GLIOMAS WITH CONCOMITANT CISPLATIN AND RADIOTHERAPY$294,555
M01 · FY2000 · RR
TREATMENT OF ANAPLASTIC GLIOMAS WITH CONCOMITANT CISPLATIN AND RADIOTHERAPY$294,555
M01 · FY2000 · RR
IMMUNOTHERAPY FOR MALIGNANT GLIOMAS$294,555
M01 · FY2000 · RR
IMMUNOTHERAPY FOR MALIGNANT GLIOMAS$294,555
M01 · FY2000 · RR
IMMUNOTHERAPY FOR MALIGNANT GLIOMAS$294,555
M01 · FY2000 · RR
BCNU, PROCARBAZINE AND RADIOTHERAPY IN TREATMENT OF ANAPLASTIC GLIOMAS$294,555
M01 · FY2000 · RR
BCNU, PROCARBAZINE AND RADIOTHERAPY IN TREATMENT OF ANAPLASTIC GLIOMAS$294,555
M01 · FY2000 · RR
ACTIVE IMMUNOTHERAPY FOR PATIENTS WITH ANAPLASTIC GLIOMA$294,555
M01 · FY2000 · RR
BCNU, PROCARBAZINE AND RADIOTHERAPY IN TREATMENT OF ANAPLASTIC GLIOMAS$241
M01 · FY2000 · RR
IMMUNOTHERAPY FOR MALIGNANT GLIOMAS$241
M01 · FY2000 · RR
TREATMENT OF ANAPLASTIC GLIOMAS WITH CONCOMITANT CISPLATIN AND RADIOTHERAPY$241
M01 · FY2000 · RR
ACTIVE IMMUNOTHERAPY FOR PATIENTS WITH ANAPLASTIC GLIOMA$241
M01 · FY2000 · RR